Antiandrogen Treatment vs Active Surveillance for Patients With Prostate Cancer

Affiliations

Comment

Dallin Busby et al. JAMA Oncol. 2022.

. 2022 Nov 10.

doi: 10.1001/jamaoncol.2022.5243. Online ahead of print.

¹ Department of Urology, Icahn School of Medicine at Mount Sinai Hospital, New York, New York.

No abstract available

Comment in

Antiandrogen Treatment vs Active Surveillance for Patients With Prostate Cancer-Reply.
Shore ND, Cooperberg MR, Tomlins SA. Shore ND, et al. JAMA Oncol. 2023 Jan 1;9(1):150-151. doi: 10.1001/jamaoncol.2022.5249. JAMA Oncol. 2023. PMID: 36385364 No abstract available.

Enzalutamide Monotherapy vs Active Surveillance in Patients With Low-risk or Intermediate-risk Localized Prostate Cancer: The ENACT Randomized Clinical Trial.
Shore ND, Renzulli J, Fleshner NE, Hollowell CMP, Vourganti S, Silberstein J, Siddiqui R, Hairston J, Elsouda D, Russell D, Cooperberg MR, Tomlins SA. Shore ND, et al. JAMA Oncol. 2022 Aug 1;8(8):1128-1136. doi: 10.1001/jamaoncol.2022.1641. JAMA Oncol. 2022. PMID: 35708696 Free PMC article. Clinical Trial.